Development of ATP-Competitive Inhibitors of KSR for the Treatment of Cancer
Award last edited on: 2/13/15

Sponsored Program
Awarding Agency
Total Award Amount
Award Phase
Solicitation Topic Code

Principal Investigator
Matthew Patricelli

Company Information

Wellspring Biosciences LLC

11119 North Torrey Pines Road Suite 125
La Jolla, CA 92037
Location: Single
Congr. District: 52
County: San Diego

Phase I

Contract Number: 1R43CA183308-01A1
Start Date: 9/22/14    Completed: 8/31/15
Phase I year
Phase I Amount
The lack of effective treatments for mutant RAS driven cancers remains a critical unmet need in modern cancer therapy. Several lines of recent evidence suggest that Kinase Suppressor of RAS (KSR) is a viable target for small molecule therapeutics. It has been established that KSR binds constitutively to MEK and transiently to RAF and Erk during active RAS signaling, and these binding events are all mediated at least in part through KSR's protein kinase domain. Recent structural studies by Wellspring's scientific co-founder, Kevan Shokat suggest that KSR's kinase domain functions as a bifunctional dynamic scaffold, bringing together key proteins for RAS signaling (MEK and RAF) and allosterically modulating RAF mediated MEK phosphorylation. A generic kinase inhibitor with the ability to modulate the allosteric switch in KSR was recently reported by Shokat and coworkers, suggesting a possible starting point to develop novel drugs that function as chemical suppressors of Ras via KSR. We are proposing to leverage the structural and biochemical findings of Shokat and colleagues, coupled with an established kinase chemical biology strategy, to generate small molecule binders of the KSR ATP site and determine their impact on KSR supported RAS signaling and cellular transformation. Our hypothesis is that binding to the KSR ATP-site will interfere with allosteric transitions required for KSR mediated RAS signaling. If successful, we will have developed a novel therapeutic strategy for the treatment of RAS driven tumors. The Phase I specific aims are: (1) Validate the ability of ATP-site directed small molecules to block KSR function (2) Develop assays for profiling KSR ATP- site occupancy. In collaboration with the Arvin Dar lab, the work outlined in this Phase I SBIR grant will provide a foundation for compound screening and characterization efforts, and expand our knowledge of the biochemical requirements for KSR mediated RAF-MEK phosphorylation to help guide compound design strategy. Subsequent Phase II studies would be aimed at identification, optimization, and characterization of reversible inhibitors of KSR and the selection of a candidate for progression into clinical development. The successful development of small molecules capable of disrupting KSR supported mutant RAS signaling would represent a major milestone in the treatment of human cancers.

Public Health Relevance Statement:

Public Health Relevance:
The Ras gene is one of the most frequently mutated oncogenes across all cancer types with approximately 30% cumulative frequency. Therapeutic strategies for reducing mutant RAS signaling, either directly or indirectly, would greatly improve patient outcomes across a wide range of cancer types.

Project Terms:
Amino Acid Substitution; Anchorage-Independent Growth; Arvin; Binding (Molecular Function); Biochemical; Biological Assay; Biology; BRAF gene; cancer therapy; cancer type; chemical genetics; Chemicals; Clinical; Collaborations; Complex; Coupled; Data; design; Development; drug development; drug discovery; Drug Targeting; effective therapy; Event; Foundations; Frequencies (time pattern); Future; Generic Drugs; Genes; Genetic; Genetic Screening; Goals; Grant; high throughput screening; Human; human KSR protein; improved; inhibitor/antagonist; Inhibitory Concentration 50; kinase inhibitor; Knock-out; Knowledge; Left; Malignant Neoplasms; Mediating; MEKs; metaplastic cell transformation; mutant; Mutate; Normal Cell; novel; novel therapeutics; Oncogenes; Oncogenic; Outcome; Pathway interactions; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; phase 2 study; Phenotype; Phosphorylation; Phosphotransferases; prevent; Property; Protein Kinase; Proteins; public health relevance; ras Genes; Refractory; Reporting; scaffold; screening; Signal Transduction; Site; Small Business Innovation Research Grant; small molecule; Therapeutic; treatment strategy; tumor; Validation; Work

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
Phase II Amount